Literature DB >> 26379838

Silencing of DUSP6 gene by RNAi-mediation inhibits proliferation and growth in MDA-MB-231 breast cancer cells: an in vitro study.

Hongming Song1, Chenyang Wu1, Chuankui Wei1, Dengfeng Li1, Kaiyao Hua1, Jialu Song1, Hui Xu1, Lei Chen1, Lin Fang1.   

Abstract

BACKGROUND: Dual-specificity phosphatase 6 (DUSP6) is a negative feedback mechanism of the mitogen-activated protein (MAP) kinase superfamily (MAPK/ERK, SAPK/JNK, p38), that is associated with cellular proliferation and differentiation. It has been reported that the expression of DUSP6 in different types of breast cancer is diverse and therefore it has altered functions in various types of breast cancer. Our aim was to explore the exact function of DUSP6 in triple-negative breast cancer cells (MDA-MB-231 cell) and to determine whether the suppression of DUSP6 by small interfering RNA (siRNA) and mircroRNA (miRNA) inhibits the growth of human MDA-MB-231 breast cancer cells.
METHODS: DUSP6-siRNA was used to inhibit the expression of DUSP6 directly and miR-145 to inhibit the expression of DUSP6 either in MDA-MB-231 breast cancer cells and successful transfection being confirmed by Real-time PCR and Western Blotting. Down regulation of DUSP6 in MDA-MB-231 cells suppressed the cell proliferation as investigated by MTT assay and colony form assay. Transwell test and Scratch assay were conducted to investigate the migration and invasion of MDA-MB-231 cells. T-test (two-tailed) was used to compare differences between groups, and the significance level was set at P<0.05.
RESULTS: DUSP6 mRNA expression and protein expression were reduced after transfection with DUSP6-siRNA directly and similar trend with transfection with miR-145. The treated group with DUSP6-siRNA or miR-145 suppressed MDA-MB-231 cells proliferation, migration and invasion, and meanwhile the cells were arrested at G0/G1 phase.
CONCLUSIONS: DUSP6 plays a role in triple-negative breast cancer cells that might promote growth in MDA-MB-231 triple-negative breast cancer cells.

Entities:  

Keywords:  DUSP6; MDA-MB-231 cells; breast cancer; miR-145; siRNA

Year:  2015        PMID: 26379838      PMCID: PMC4565221     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  19 in total

Review 1.  RNAi therapeutics and applications of microRNAs in cancer treatment.

Authors:  Keita Uchino; Takahiro Ochiya; Fumitaka Takeshita
Journal:  Jpn J Clin Oncol       Date:  2013-04-16       Impact factor: 3.019

2.  Alterations of microRNAs are associated with impaired growth of MCF-7 breast cancer cells induced by inhibition of casein kinase 2.

Authors:  Dengfeng Li; Lei Chen; Zhen Hu; Hua Li; Jia Li; Chuankui Wei; Yixiang Huang; Hongming Song; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 3.  Improvement of survival and prospect of cure in patients with metastatic breast cancer.

Authors:  Yee Chung Cheng; Naoto T Ueno
Journal:  Breast Cancer       Date:  2011-05-13       Impact factor: 4.239

4.  Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.

Authors:  Toru Furukawa; Rumi Fujisaki; Yoshitaro Yoshida; Naomi Kanai; Makoto Sunamura; Tadayoshi Abe; Kazunori Takeda; Seiki Matsuno; Akira Horii
Journal:  Mod Pathol       Date:  2005-08       Impact factor: 7.842

5.  miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3.

Authors:  Myriem Boufraqech; Lisa Zhang; Meenu Jain; Dhaval Patel; Ryan Ellis; Yin Xiong; Mei He; Naris Nilubol; Maria J Merino; Electron Kebebew
Journal:  Endocr Relat Cancer       Date:  2014-04-29       Impact factor: 5.678

Review 6.  The dual-specificity MAP kinase phosphatases: critical roles in development and cancer.

Authors:  O Bermudez; G Pagès; C Gimond
Journal:  Am J Physiol Cell Physiol       Date:  2010-05-12       Impact factor: 4.249

7.  Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.

Authors:  Koji Okudela; Takuya Yazawa; Tetsukan Woo; Masashi Sakaeda; Jun Ishii; Hideaki Mitsui; Hiroaki Shimoyamada; Hanako Sato; Michihiko Tajiri; Nobuo Ogawa; Munetaka Masuda; Takashi Takahashi; Haruhiko Sugimura; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

8.  siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breast cancer cells.

Authors:  Xiao-Yu Li; Qi-Feng Luo; Chuan-Kui Wei; Deng-Feng Li; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

Review 9.  Non-viral nanocarriers for siRNA delivery in breast cancer.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

10.  DUSP6 is a novel transcriptional target of p53 and regulates p53-mediated apoptosis by modulating expression levels of Bcl-2 family proteins.

Authors:  Sujan Piya; Ji Young Kim; Jeehyeon Bae; Dai-Wu Seol; Ae Ran Moon; Tae-Hyoung Kim
Journal:  FEBS Lett       Date:  2012-10-26       Impact factor: 4.124

View more
  6 in total

Review 1.  Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.

Authors:  Mariana Tannús Ruckert; Pamela Viani de Andrade; Verena Silva Santos; Vanessa Silva Silveira
Journal:  Cell Mol Life Sci       Date:  2019-04-13       Impact factor: 9.207

2.  BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.

Authors:  Katja F Krämer; Natalia Moreno; Michael C Frühwald; Kornelius Kerl
Journal:  Int J Mol Sci       Date:  2017-07-16       Impact factor: 5.923

3.  DUSP6 protects murine podocytes from high glucose‑induced inflammation and apoptosis.

Authors:  Liqiang Chen; Yaokun Wang; Haiyan Luan; Guangyu Ma; Huiming Zhang; Guang Chen
Journal:  Mol Med Rep       Date:  2020-07-09       Impact factor: 2.952

4.  Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.

Authors:  Muhammad Khairi Ahmad; Nur Ainina Abdollah; Nurul Husna Shafie; Narazah Mohd Yusof; Siti Razila Abdul Razak
Journal:  Cancer Biol Med       Date:  2018-02       Impact factor: 4.248

5.  Down-regulation of CCL17 in cancer-associated fibroblasts inhibits cell migration and invasion of breast cancer through ERK1/2 pathway.

Authors:  Junjie Li; Chunli Yang; Jingshi Yang; Liqun Zou
Journal:  Cancer Manag Res       Date:  2019-08-07       Impact factor: 3.989

6.  Dual-specificity phosphatase (DUSP6) in human glioblastoma: epithelial-to-mesenchymal transition (EMT) involvement.

Authors:  Candida Zuchegna; Erika Di Zazzo; Bruno Moncharmont; Samantha Messina
Journal:  BMC Res Notes       Date:  2020-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.